Dr. med. Dieter Köberle
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Borner M, Roth A, Lanz D, Brauchli P, Honegger H, Köberle D, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8.
Feb 1, 2005A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Feb 1, 2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8
Borner M M, Roth A D, Lanz D, Brauchli P, Honegger H, Köberle Dieter, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Thürlimann B, Rochlitz C, Aebi S, Perey L, Pagani O, Ballabeni P, Senn I, Köberle D, Hess D, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85:247-54.
Jun 1, 2004Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Jun 1, 2004Breast Cancer Res Treat 2004; 85:247-54
Thürlimann Beat, Rochlitz Christoph, Aebi Stefan, Perey Lucien, Pagani Olivia, Ballabeni Pierluigi, Senn Isabella, Köberle Dieter, Hess Dagmar, Goldhirsch Aron
Re: Playing the old piano: another tune for endocrine therapy
Köberle D, Perey L, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK). Re: Playing the old piano: another tune for endocrine therapy. Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7.
Apr 7, 2004Re: Playing the old piano: another tune for endocrine therapy
Apr 7, 2004Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7
Köberle Dieter, Perey Lucien, Thürlimann Beat, Swiss Group for Clinical Cancer Research (SAKK)
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer
Köberle D, Thürlimann B. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. Expert review of anticancer therapy 2001; 1:169-76.
Aug 1, 2001Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer
Aug 1, 2001Expert review of anticancer therapy 2001; 1:169-76
Köberle Dieter, Thürlimann Beat
Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
Gessner U, Köberle D, Thürlimann B, Bacchus L, Horisberger B. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22.
Mar 1, 2000Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
Mar 1, 2000Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22
Gessner U, Köberle Dieter, Thürlimann Beat, Bacchus L, Horisberger B
[Yellow nail syndrome]
Köberle D, Henz S, Flury D, Mayer R. [Yellow nail syndrome]. Schweizerische medizinische Wochenschrift 1999; 129:1342.
Sep 18, 1999[Yellow nail syndrome]
Sep 18, 1999Schweizerische medizinische Wochenschrift 1999; 129:1342
Köberle Dieter, Henz Samuel, Flury D, Mayer R
Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Köberle D, Bacchus L, Thürlimann B, Senn H. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7.
Jan 1, 1999Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Jan 1, 1999Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7
Köberle Dieter, Bacchus L, Thürlimann Beat, Senn H J
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Engler H, Köberle D, Thürlimann B, Senn H, Riesen W. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85.
Nov 1, 1998Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Nov 1, 1998Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85
Engler H, Köberle Dieter, Thürlimann Beat, Senn H J, Riesen W F